Stopping Cancer Before It Starts

Antiva is developing a novel topical antiviral to treat pre-cancerous cervical lesions caused by human papillomavirus (HPV) and to treat the HPV infections that cause these lesions. Currently, there is no approved treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease, such as precancerous cervical lesions or cancer. The only treatments available for pre-cancerous cervical lesions are invasive in-office surgical-based options with risks to long-term reproductive health. If successful, our therapy will give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed and provide a non-surgical option for women whose disease has progressed to pre-cancerous lesions.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV infection and pre-cancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.

Antiva in the
News

June 13, 2024

Antiva Biosciences Announces Formation of Scientific and Development Advisory Board Read more

October 19, 2023

Antiva Biosciences Strengthens Leadership with Key New Appointments Read more

May 5, 2023

ANNOUNCEMENT: ASCCP Presents Dr. Tom Cox with Lifetime Achievement Award Read more